BerGenBio to present recent highlights from its clinical trials with selective AXL inhibitor BGB324 at DNB’s 8th Annual Nordic Healthcare Conference
· Six ph II clinical trials ongoing with first-in-class highly selective AXL inhibitor BGB324. · Monotherapy data at 19% RR in relapsed/refractory AML and high-risk MDS reported at ASH. · 50% CBR with BGB324 in combination with erlotinib in NSCLC reported at World Lung. · BGB324 in combination with docetaxel as last line therapy in NSCLC showing very promising early efficacy at 66% CBR.Bergen, Norway, 14 December 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces